Call for Papers

We are now accepting abstracts for consideration.

All colleagues are encouraged to submit an abstract for an oral and/or poster presentation.

All International Attendees, please submit your abstract by clicking the button below:

International Abstract Submission

All Local Australian / New Zealander Attendees, please submit your abstract by clicking the button below:

Local Abstract Submission


Key Dates

  • ORAL Abstract Submission Deadline Date: March 29, 2018
  • POSTER Abstract Submission Deadline Date: April 16, 2018
  • First Round of Oral Abstract Acceptance Confirmations (via e-mail):  April 2018
  • First Round of Poster Abstract Acceptance Confirmations (via e-mail):  May 2018
  • Oral & Poster Presenter Registration Due Date:  May 31, 2018
  • Last Day to Edit Abstract:  June 1, 2018

Submission Topics

  • Advanced Digital Technologies
  • Cutaneous malignancies of the head and neck
  • Epidemiology and prevention
  • Functional Outcomes
  • Immunology, Immunotherapy and systemic treatment
  • Management of Head and Neck Squamous Cell Carcinoma
  • Maxillofacial Prosthodontic Rehabilitation
  • Molecular Biology and Therapeutics
  • Non-Squamous Cell Malignancies of the Head and Neck (thyroid, sarcomas, salivary gland and sinus cancers)
  • Palliative Care
  • Pre-Treatment Planning for Head and Neck Malignancies and Quality Improvement
  • Toxicity, Quality of Life, Survivorship

2018 Abstract Guidelines

  • The Conference will consider both Oral and Poster Abstracts for presentation
  • Online abstract submissions are required
  • Abstracts will be published as submitted. Proof and edit your submission accordingly
  • Presenting authors must pay the registration fee and attend the meeting. Authors of accepted abstracts are not provided with travel funds
  • All accepted abstracts will be published and distributed electronically in the Conference Syllabus
  • Body of abstract: purpose of the study, methods used, summary of the results and conclusion reached
  • Use standard abbreviations in parentheses after the full word the first time it appears
  • Abstracts will be published as submitted. Proof and edit your submission accordingly

Abstract Scoring Criteria

  • Does the abstract address an important and novel question?
  • Does the study design permit the question to be answered?
  • Are the endpoints of the study clearly defined?
  • Is there an appropriate use of statistics?
  • Are the methods described in sufficient detail?
  • Are the conclusions supported by the data?
  • Has the research been accepted for presentation at another medical meeting?

Specific questions for prospective Clinical Trials:

  • What was the scientific hypothesis and primary endpoint?
  • What was the eligibility criteria and study patient characteristics?
  • What statistical model and assumptions were used?
  • What was the toxicity assessment?
  • What were the limitations?
  • Is there a rationale, either clinical or laboratory, underlying the study design?
  • Is it either promising enough to pursue or negative enough (for a rational therapy) that presentation would prevent other investigators from wasting efforts?

Specific questions for retrospective reviews:

  • Is the group of patients reasonably homogeneous?
  • Have attempts been made to account for biases inherent in retrospective reviews?

Disclosure Policy
Authors are required to disclose relationships with commercial interests. A commercial interest is defined as “any entity developing, producing, marketing, re-selling or distributing healthcare goods or services consumed by or used on patients.”

We employ several strategies to ensure absence of bias:

  • Presenters are required to provide disclosure of relationships with commercial interests.
  • Presenters are required to provide a balanced view of therapeutic options.
  • All abstracts undergo a rigorous peer review process.
  • Potential conflicts are managed by: additional committee review, advance slide review and session audits.

General Information

  • Oral Abstracts must be received by 11:59 p.m, Thursday, March 29, 2018
  • Poster Abstracts must be received by 11:59 p.m, Monday, April 16, 2018
  • Please be sure to click “submit” before 11:59 p.m., as the abstract may not fully transfer and you risk being ineligible by having an “incomplete” status. Abstracts received after the deadline will not be accepted and incomplete abstracts will be considered ineligible for review.
  • Summaries of new, ongoing and updated research in the areas of head and neck oncology are acceptable for submission and presentation.
  • Presentations must give a balanced view of therapeutic options. Brand names of pharmaceuticals and trade names of medical devices should not be used in the title or body of the abstract. Use of generic names will contribute to impartiality. If the session material or content includes trade names, where available trade names from several companies should be used, not just trade names from a single company. For example, if it is appropriate to do so, use the term “radiosurgery” instead of listing a specific machine name. Planning committees have the right to change the abstract if they feel that the use of a trade name may be mistaken for commercial propaganda and may replace proprietary names with generic names.
  • Abstracts containing reports on the discovery of scientific research will be evaluated on the following criteria:
      • The content does not contain patient care recommendations.
      • The content is at the level of biology, physiology or physics and far from a discussion of products that are prescribed to patients.
      • The content is about the discovery process itself and not about treatment or diagnostics.
      • The content covers research results so early in the discovery process that there is no product developed yet.
      • The target learners are scientists who are also participating in the discovery process.
  • Abstracts may be submitted from any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients reporting on the discovery of their scientific research. Such presentations will be subject to a rigorous peer review process to ensure the validity of the research review process, results, and conclusions. In addition, abstract content is subject to change after review and evaluation so that it is not biased towards any proprietary or commercial interests.
  • The planning committees will exercise all rights in ensuring that abstracts reporting the discovery of scientific research remain in compliance with the CME offered. If accepted, the abstract must be presented by a co-author with no relevant financial relationship or any commercial interest.
  • It is the responsibility of the submitting author to obtain disclosure information from all co-authors and to report this information electronically during the abstract submission process.